Clinical Trial

Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 24, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Through the MALDI-TOF MS platform, explore the proteomics and peptidomics differences of fasting serum/plasma and urine between non pregnant people with normal glucose tolerance test and prediabetes /diabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively; To explore the role of its proteomics and peptidomics differences in the diagnosis of prediabetes and diabetes, and to establish a new method of differential diagnosis by using the omics data and key characteristic peaks to find potential new diagnostic markers.
Trial Details
NCT Number NCT06097065
Lead Sponsor Zhujiang Hospital
Conditions Prediabetes, Diabetes Mellitus, Gestational Diabetes Mellitus, Proteomics
Enrollment 2,860 participants
Start Date 2022-05-20
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-10-24